https://www.selleckchem.com/pr....oducts/Cyclopamine.h
To determine the potential impact on visual outcomes of delayed treatment initiation in patients with neovascular age-related macular degeneration (nAMD). Post hoc analysis of anti-vascular endothelial growth factor treatment-naïve patients with nAMD from HARBOR. Time to treatment was defined as first ranibizumab injection date minus screening date. Comparisons were made between the prompt (≤ 6 days) versus delayed ( 10 days) treatment groups. Main outcome measures were best-corrected visual acuity (BCVA) change over time, BCVA,
Like
Comment
Share
